VeriSIM Life awarded US government agreement to advance drug development
VeriSIM Life has announced that it has entered into an agreement with the United States Department of War to advance computational new approach methodologies for medical countermeasure development and safety assessment.
Under the agreement announced on 28 September, VeriSIM Life will use its BIOiSIM® platform to develop and evaluate computational models that integrate biological, experimental and drug-specific data to better understand how findings from preclinical systems translate to humans.
A key focus of the work is determining where computational approaches can reduce the need for animal studies while maintaining the scientific rigour required for drug development decisions. The programme will evaluate how these methods can be used alongside experimental data to guide study design and identify where additional testing is most informative.
"We have spent years building BIOiSIM around one of the most fundamental challenges in drug development: understanding what is likely to translate to humans before committing to more experiments," said Dr. Jo Varshney, Founder and CEO of VeriSIM Life. "This program gives us an opportunity to apply that work to an important government need and demonstrate where computational methods can meaningfully reduce animal use while improving the quality of translational decisions."
BIOiSIM combines mechanistic bio simulation with machine learning/AI to evaluate pharmacokinetics, safety, efficacy and other factors that influence therapeutic translation. VeriSIM Life has applied the platform across discovery and development programs and has worked with pharmaceutical companies, research institutions and government agencies to evaluate and validate computational approaches to drug development.
This project was partially funded by the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense’s Joint Project Lead for CBRN Enabling Technologies under Agreement W911SR-26-9-A036.
